Denali therapeutics announces initiation of bla filing for accelerated approval of tividenofusp alfa for the treatment of hunter syndrome (mps ii) and positive ongoing interactions with fda on dnl126 through start program

South san francisco, calif., april 02, 2025 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), today announced that the company's initiation of a rolling submission of a biologics license application (bla) for accelerated approval of tividenofusp alfa for the treatment of hunter syndrome (mps ii) has been received by the center for drug evaluation and research (cder) of the u.s. food and drug administration (fda). denali continues to have regular, collaborative, and productive engagement with cder and is aligned with cder on the content of the bla data package, including the use of cerebrospinal fluid heparan sulfate (csf hs) as a surrogate endpoint to support an accelerated approval, as well as the full approval conversion path. denali expects to complete the bla submission in the first half of may 2025 and continues to prepare for a potential commercial launch in the u.s. in late 2025 or early 2026.
DNLI Ratings Summary
DNLI Quant Ranking